$heff's $tation of $tocks & $olid DD

[$heff]

DD Post on LJPC. The goal of LJPC (Lajolla Pharma) is to eventually uplist to a major exchange and to get larger investors on board. They currently have Baker Brothers, Tang Mngmt, RTW Investments, & Boxer Capital Group. This is an opportunity to follow the Baker Brothers in an early investment. They are the kingpin investors in the biotech space & to my knowledge this is the first time I have seen them make a significant investment in an OTCBB stock. The company has 101m in the float, 220m O/S, and 861m shares fully diluted. The company has strong institutional investing so that risk is still high but is mitigated with the early stakeholders from the restructuring that they have in the company. LJPC Corporate Presentation Oct 2013
http://bit.ly/1cBvuVJ




LJPC Financial Stats



Recent Financing



LJPC Recent Capital Restructuring





La Jolla Pharmaceutical Company Announces Complete Enrollment of Phase 2 Clinical Trial of GCS-100 in Chronic Kidney Disease - http://yhoo.it/1d6bR6C

Announced that it has completed enrollment of its placebo-controlled, randomized Phase 2 clinical trial of GCS-100 in patients with chronic kidney disease ("CKD"). A total of 121 patients with Stage 3b or 4 CKD were enrolled in the study. The Company expects to announce data on the primary endpoint in April 2014 and the full data package before the end of the second quarter 2014.

LJPC Corporate Highlights



A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease - Full Text View - ClinicalTrials.gov http://1.usa.gov/1drz8xQ

Data from 2013 ASN Conference: Galectin-3, Target of GCS-100, Inversely Correlates with eGFR http://ljpc.com/2013/11/



Large Institutional Ownership..with Baker Brothers being one of those owners.


Strong Company Management


Deep Product Pipeline


LJPC Summary

LJPC Corporate Presentation Oct 2013
http://bit.ly/1cBvuVJ